Human Formulations

Nimesulide 100 mg + Paracetamol 325 mg Uncoated Tablet

Nimesulide 100 mg + Paracetamol 325 mg Uncoated Tablet is a uncoated tablet formulated with Nimesulide 100 mg + Paracetamol 325 mg. The active ingredient profile is Nimesulide; Paracetamol, placing the product in the nsaid + analgesic combination category

TabletsNon-Beta-Lactam Tablets Single Ingredient Uncoated Tablet
Sterile injectable formulation

Product information

Product Line
Human Formulations
Category
Tablets, Non-Beta-Lactam Tablets
Dosage Form
Uncoated Tablet
Product Type
Single Ingredient

Available strengths

Nimesulide 100 mg + Paracetamol 325 mg

Description

Nimesulide 100 mg + Paracetamol 325 mg Uncoated Tablet is a uncoated tablet formulated with Nimesulide 100 mg + Paracetamol 325 mg. The active ingredient profile is Nimesulide; Paracetamol, placing the product in the nsaid + analgesic combination category. This formulation combines Nimesulide with Paracetamol and, in some variants, an enzyme component for clinician-directed pain/inflammation management where locally approved. The uncoated presentation is an oral solid-dosage form and should be described according to the approved finished-product specification. For website cataloguing, composition, strength, dosage form and release/coating characteristics should be displayed prominently and consistently. The description should remain factual and should not include unapproved cure, superiority, guaranteed-result or broad therapeutic claims. Clinical selection should depend on diagnosis, patient-specific factors, contraindications, concomitant medicines and the prescriber’s judgement. Prescription status, precautions, interactions, adverse effects and dosing must be checked against the current approved product label before publication. Manufacturer, licence, storage, shelf-life, pack configuration and market-specific regulatory details should be added only from verified product documentation.
WHO-GMP Sourced
Sterile Supply
Regulatory Documentation
Quality Assured